Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
Opus Genetics (Nasdaq: IRD) announced that Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, will present a corporate update at Chardan's 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025 at 12:00 p.m. ET. The company noted a live and archived webcast will be available via the Opus Genetics investor website under Events.
Opus Genetics (Nasdaq: IRD) ha annunciato che Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, terrà un aggiornamento aziendale al 9° Congresso Annuale di Genetic Medicines di Chardan il martedì 21 ottobre 2025 alle ore 12:00 ET. L'azienda ha indicato che sarà disponibile una trasmissione in diretta e una registrazione archiviata tramite il sito investitori di Opus Genetics nella sezione Eventi.
Opus Genetics (Nasdaq: IRD) anunció que Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, presentará una actualización corporativa en la 9. Conferencia anual de medicamentos genéticos de Chardan el martes 21 de octubre de 2025 a las 12:00 p. m. ET. La empresa señaló que habrá una transmisión en vivo y una grabación disponible a través del sitio de inversores de Opus Genetics en la sección Eventos.
Opus Genetics (Nasdaq: IRD)는 Ash Jayagopal 박사, MBA, 최고 과학 및 개발 책임자가 Chardan의 제9회 연례 유전의약품 컨퍼런스에서 기업 업데이트를 발표할 예정이라고 발표했습니다. 일정은 2025년 10월 21일 화요일 오후 12:00(동부 표준시)에 열립니다. 회사는 라이브 및 아카이브 웹캐스트가 Opus Genetics 투자자 웹사이트의 이벤트 섹션에서 이용 가능하다고 밝혔습니다.
Opus Genetics (Nasdaq: IRD) a annoncé que Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, présentera une mise à jour corporative lors de la 9e conférence annuelle sur les médicaments génétiques de Chardan le mardi 21 octobre 2025 à 12h00 ET. La société a précisé qu’un webcast en direct et une archive seront disponibles via le site investisseurs d’Opus Genetics sous la rubrique Événements.
Opus Genetics (Nasdaq: IRD) gab bekannt, dass Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, eine Unternehmensaktualisierung auf der 9. Jahreskonferenz für genetische Arzneimittel von Chardan am Dienstag, den 21. Oktober 2025 um 12:00 Uhr Eastern Time vorstellen wird. Das Unternehmen gab an, dass ein Live- und Archiv-Webcast über die Investoren-Website von Opus Genetics unter Veranstaltungen verfügbar sein wird.
Opus Genetics (Nasdaq: IRD) أعلنت أن آش جياجوبال، الدكتوراه، MBA، المدير العلمي والتنفيذي، سيقدم تحديثاً للشركة في المؤتمر السنوي التاسع للأدوية الوراثية الذي تنظمه تشاردان، يوم الثلاثاء 21 أكتوبر 2025 الساعة 12:00 ظهرًا بتوقيت شرق الولايات المتحدة. أشارت الشركة إلى أن بثاً مباشراً وبثاً محتوياً سيكون متاحاً عبر موقع المستثمرين لـ Opus Genetics ضمن قسم الأحداث.
Opus Genetics (纳斯达克：IRD)宣布，Ash Jayagopal，博士，MBA，首席科学与开发官，将在Chardan 第九届年度基因药物会议上进行公司更新，时间为美国东部时间2025年10月21日周二中午12:00。公司指出，将通过 Opus Genetics 投资者网站的“事件”板块提供现场和存档的网络广播。
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, announced today that Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, will present a corporate update at Chardan's 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025, at 12:00 p.m. ET.
A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company’s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
FAQ
When will Opus Genetics (IRD) present at Chardan's 9th Annual Genetic Medicines Conference?
Who is presenting for Opus Genetics (IRD) at the October 21, 2025 conference?
How can investors watch the Opus Genetics (IRD) presentation on October 21, 2025?
What topics will Opus Genetics (IRD) cover in the October 21, 2025 corporate update?
Is the Opus Genetics (IRD) webcast for the Chardan conference free to access?
